Erratum: Exploring the distribution of genetic markers of pharmacogenomics relevance in brazilian and mexican populations (PLoS ONE (2015) 9:11 (e112640) DOI: 10.1371/journal.pone.0112640);Exploring the distribution of genetic markers of pharmacogenomics relevance in Brazilian and Mexican populations

PLoS ONE

Volumn 9, Issue 11, 2014, Pages

  Bonifaz Peña, Vania ^a   Contreras, Alejandra V ^a   Struchiner, Claudio Jose ^b   Roela, Rosimeire A ^c   Furuya Mazzotti, Tatiane K ^c   Chammas, Roger ^c   Rangel Escareño, Claudia ^a,g   Uribe Figueroa, Laura ^a,i   Gómez Vázquez, María José ^a,j   McLeod, Howard L ^d,h   Hidalgo Miranda, Alfredo ^a   Parra, Esteban J ^e   Fernández López, Juan Carlos ^a   Suarez Kurtz, Guilherme ^f  

^a INSTITUTO NACIONAL DE MEDICINA GENÓMICA   (Mexico)

^b INSTITUTO OSWALDO CRUZ   (Brazil)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

^d H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^e UNIVERSITY OF TORONTO   (Canada)

^f INSTITUTO NACIONAL DE CÂNCER   (Brazil)

^g CLAREMONT GRADUATE UNIVERSITY   (United States)

^h Pharmacogenomics Department Pharmacogenetics for Every Nation Initiative   (United States)

ⁱ Thermo Fisher Scientific   (United States)

^j UNIVERSITY OF CAMBRIDGE   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ABCC8 GENE; ADH1A GENE; ARTICLE; BRAZIL; BRAZILIAN; CHST3 GENE; CONTROLLED STUDY; CYP19A1 GENE; CYP1A1 GENE; CYP1A2 GENE; CYP2B6 GENE; CYP2D6 GENE; CYP3A4 GENE; GENE; GENE FREQUENCY; GENETIC MARKER; GENETIC VARIABILITY; GENOTYPE; HUMAN; MESTIZO; MEXICAN; MEXICO; PHARMACOGENETICS; PHARMACOGENOMICS; PON1 GENE; PPARD GENE; PPARG GENE; SINGLE NUCLEOTIDE POLYMORPHISM; SLC22A4 GENE; SLC28A1 GENE; SLC28A2 GENE; SLC28A3 GENE; UGT1A1 GENE; UGT2B7 GENE; VKORC1 GENE; ZAPOTEC (PEOPLE); GENE LOCUS; GENETICS; HAPLOTYPE; POPULATION GENETICS; PROCEDURES; STATISTICAL MODEL;

CYTOCHROME P450 2D6; GLUCURONOSYLTRANSFERASE; UGT1A1 ENZYME; VITAMIN K EPOXIDE REDUCTASE; VKORC1 PROTEIN, HUMAN;

BRAZIL; CYTOCHROME P-450 CYP2D6; GENE FREQUENCY; GENETIC LOCI; GENETICS, POPULATION; GENOTYPE; GLUCURONOSYLTRANSFERASE; HAPLOTYPES; HUMANS; LOGISTIC MODELS; MEXICO; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; VITAMIN K EPOXIDE REDUCTASES;

EID: 84913554859     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0122161     Document Type: Erratum

References (48)

1. Klein TE, Altman RB, Eriksson N, Gage BF, Kimmel SE, et al. (2009) Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med 360: 753-764.
2. The Single Nucleotide Polymorphism database website. Available: http://www.ncbi.nlm.nih.gov/snp/?term=9923231. Accessed 2013 December 17.
3. Rede Nacional de Farmacogenética website. Available: http://www.refargen.org.br/article.php3?id=50. Accessed 2014 January 14.
4. Limdi NA, Wadelius M, Cavallari L, Eriksson N, Crawford DC, et al. (2010) Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups. Blood 115: 3827-3834.
5. Suarez-Kurtz G (2011) Population diversity and the performance of warfarin dosing algorithms. Br J Clin Pharmacol 72: 451-453.
6. Ramos E, Doumatey A, Elkahloun AG, Shriner D, Huang H, et al. (2014) Pharmacogenomics, ancestry and clinical decision making for global populations. Pharmacogenomics J 14(3): 217-22.
7. Instituto Brasileiro de Geografia e Estatistica website. Available: www.ibge.gov.br/home/estatistica/populacao/estimativa2012/. Accessed 2013 December 12.
8. Instituto Nacional de Estadística y Geografía website. Available: http://www.inegi.org.mx/sistemas/olap/proyectos/bd/consulta.asp?p=17118&c=27769&s=est. Accessed 2013 December 30.
9. Salzano FM, Bortolini MC (2002) The Evolution and Genetics of Latin American Populations. Cambridge: Cambridge University Press.
10. Pena SD, Di Pietro G, Fuchshuber-Moraes M, Genro JP, Hutz MH, et al. (2011) The genomic ancestry of individuals from different geographical regions of Brazil is more uniform than expected. PLoS One 6: e17063.
11. Silva-Zolezzi I, Hidalgo-Miranda A, Estrada-Gil J, Fernandez-Lopez JC, Uribe-Figueroa L, et al. (2009) Analysis of genomic diversity in Mexican Mestizo populations to develop genomic medicine in Mexico. Proc Natl Acad Sci U S A 106: 8611-8616.
12. Bryc K, Velez C, Karafet T, Moreno-Estrada A, Reynolds A, et al. (2010) Colloquium paper: genomewide patterns of population structure and admixture among Hispanic/Latino populations. Proc Natl Acad Sci U S A. 11; 107 Suppl 2: 8954-61.
13. Galanter JM, Fernandez-Lopez JC, Gignoux CR, Barnholtz-Sloan J, Fernandez-Rozadilla C, et al. (2012) Development of a panel of genome-wide ancestry informative markers to study admixture throughout the Americas. PLoS Genet 8(3): e1002554.
14. Burmester JK, Sedova M, Shapero MH, Mansfield E (2010) DMET microarray technology for pharmacogenomics-based personalized medicine. Methods Mol Biol 632: 99-124.
15. Price AL, Patterson N, Yu F, Cox DR, Waliszewska A, et al. (2007) A Genomewide Admixture Map for Latino Populations. Am. J. Hum. Genet 80(6): 1024-1036.
16. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, et al. (2007) PLINK: a tool set for wholegenome association and population-based linkage analyses. Am J Hum Genet 81: 559-575.
17. Altshuler DM, Gibbs RA, Peltonen L, Altshuler DM, Gibbs RA, et al; The International HapMap 3 Consortium (2010) Integrating common and rare genetic variation in diverse human populations. Nature 467: 52-58.
18. Pritchard JK, Stephens M, Donnelly P (2000) Inference of population structure using multilocus genotype data. Genetics 155: 945-959.
19. Falush D, Stephens M, Pritchard JK (2003) Inference of population structure using multilocus genotype data: linked loci and correlated allele frequencies. Genetics 164: 1567-1587.
20. Hubisz MJ, Falush D, Stephens M, Pritchard JK (2009) Inferring weak population structure with the assistance of sample group information. Mol Ecol Resour. 9(5): 1322-32.
21. Reich D, Patterson N, Campbell D, Tandon A, Mazieres S, et al. (2012) Reconstructing Native American population history. Nature 16; 488(7411): 370-4.
22. Moreno EA, Gignoux CR, Fernández JC, Zakharia F, Sikora M (2014) The genetics of Mexico recapitulates Native American substructure and affects biomedical traits. Science 344(6189)): 1280-1285.
23. Patterson N, Price AL, Reich D (2006) Population structure and eigenanalysis. PLoS Genet 2(12): e190.
24. Stephens M, Donnelly P (2003) A comparison of bayesian methods for haplotype reconstruction from population genotype data. Am J Hum Genet 73(5): 1162-9.
25. Stephens M, Smith NJ, Donnelly P (2001) A new statistical method for haplotype reconstruction from population data. Am J Hum Genet 68: 978-989.
26. Stephens M, Scheet P (2005) Accounting for decay of linkage disequilibrium in haplotype inference and missing-data imputation. Am J Hum Genet 76: 449-462.
27. Suarez-Kurtz G, Pena SD, Hutz MH (2012) Application of the F(ST) statistics to explore pharmacogenomic diversity in the Brazilian population. Pharmacogenomics 13: 771-777.
28. Harrell FE (2002) Regression Modeling Strategies With Applications to Linear Models, Logistic Regression, and Survival Analysis. New York: Springer.
29. R Development Core Team (2011) R: a language and environment for statistical computing. Vienna, Austria: the R Foundation for Statistical Computing.
30. Contreras AV, Monge-Cazares T, Alfaro-Ruiz L, Hernandez-Morales S, Miranda-Ortiz H, et al. (2011) Resequencing, haplotype construction and identification of novel variants of CYP2D6 in Mexican Mestizos. Pharmacogenomics 12: 745-756.
31. Hicks JK, Swen JJ, Gaedigk A (2014) Challenges in CYP2D6 Phenotype Assignment from Genotype Data: A Critical Assessment and Call for Standardization. Curr Drug Metab 15: 218-232.
32. Kim SY, S Hong Y, K Shim E, Kong SY, Shin A, et al. (2013) S-1 plus irinotecan and oxaliplatin for the first-line treatment of patients with metastatic colorectal cancer: a prospective phase II study and pharmacogenetic analysis. Br J Cancer 17; 109(6): 1420-7.
33. Cha PC, Mushiroda T, Zembutsu H, Harada H, Shinoda N, et al. (2009) Single nucleotide polymorphism in ABCG2 is associated with irinotecan-induced severe myelosuppression. J Hum Genet 54(10): 572-80.
34. Côté JF, Kirzin S, Kramar A, Mosnier JF, Diebold MD, et al. (2007) UGT1A1 polymorphism can predict hematologic toxicity in patients treated with irinotecan. Clin Cancer Res 13(11): 3269-75.
35. Saito Y, Sai K, Maekawa K, Kaniwa N, Shirao K, et al. (2009) Close association of UGT1A9 IVS1+399C> T with UGT1A1∗28, ∗6, or ∗60 haplotype and its apparent influence on 7-ethyl-10-hydroxycamptothecin (SN-38) glucuronidation in Japanese. Drug Metab Dispos 37(2): 272-6.
36. Rieder MJ, Reiner AP, Gage BF, Nickerson DA, Eby CS, et al. (2005) Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med 352: 2285-2293.
37. Weir BS, Cardon LR, Anderson AD, Nielsen DM, Hill WG (2005) Measures of human population structure show heterogeneity among genomic regions. Genome Res 15: 1468-1476.
38. Elhaik E (2012) Empirical distributions of F(ST) from large-scale human polymorphism data. PLoS One 7: e49837.
39. Li JZ, Absher DM, Tang H, Southwick AM, Casto AM, et al. (2008) Worldwide human relationships inferred from genome-wide patterns of variation. Science 319: 1100-1104.
40. Auton A, Bryc K, Boyko AR, Lohmueller KE, Novembre J, et al. (2009) Global distribution of genomic diversity underscores rich complex history of continental human populations. Genome Res 19: 795-803.
41. Henn BM, Cavalli-Sforza LL, Feldman MW (2012) The great human expansion. Proc Natl Acad Sci U S A 109: 17758-17764.
42. Deshpande O, Batzoglou S, Feldman MW, Cavalli-Sforza LL (2009) A serial founder effect model for human settlement out of Africa. Proc Biol Sci 276: 291-300.
43. Telles EE (2002) Racial Ambiguity among the Brazilian Population. Ethnic and Racial Studies 25(3): 415-441.
44. Bastos JL, Peres MA, Peres KG, Dumith SC, Gigante DP (2008) [Socioeconomic differences between self- and interviewer-classification of color/race]. Rev Saude Publica 42: 324-334.
45. Suarez-Kurtz G, Pena SD, Struchiner CJ, Hutz MH (2012) Pharmacogenomic Diversity among Brazilians: Influence of Ancestry, Self-Reported Color, and Geographical Origin. Front Pharmacol 3: 191.
46. Perera MA, Cavallari LH, Johnson JA (2014) Warfarin pharmacogenetics: an illustration of the importance of studies in minority populations. Clin Pharmacol Ther 95(3): 242-4.
47. Perini JA, Struchiner CJ, Silva-Assuncao E, Santana IS, Rangel F, et al. (2008) Pharmacogenetics of warfarin: development of a dosing algorithm for brazilian patients. Clin Pharmacol Ther 84: 722-728.
48. Suarez-Kurtz G, Pena SD (2006) Pharmacogenomics in the Americas: the impact of genetic admixture. Curr Drug Targets 7(12): 1649-58.